Emergent BioSolutionsSTU:ER4 +0.90%55 Days Payable is 59.81 as of Mar. 2026, which is 11% below its 10-year median of 67.27. GuruFocus rates STU:ER4 with a GF Score™ of 55/100 and a GF Value™ of €4.18 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 919 Drug Manufacturers companies, Emergent BioSolutions ranks worse than 64.85% on this metric.
Emergent BioSolutions Days Payable Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs ELTP, NIKA, EOLS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Days Payable distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Emergent BioSolutions's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (STU:ER4) has a Days Payable of 59.81 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emergent BioSolutions and its competitors. This is 11% below median its historical median of 67.27. Over the past decade, Emergent BioSolutions' Days Payable has ranged from 46.37 to 104.93. According to the industry distribution chart, Emergent BioSolutions ranks #596 out of 919 companies in the Drug Manufacturers industry, placing it in the top 64.9%.
Is Emergent BioSolutions' Days Payable too high?
Emergent BioSolutions' current Days Payable of 59.81 is 11% below median its 10-year median of 67.27. Over the past 10 years, this metric has ranged from a low of 46.37 to a high of 104.93. The Drug Manufacturers industry median Days Payable is 90.69. Emergent BioSolutions' value of 59.81 is 34.1% below this industry median. Based on the distribution chart, Emergent BioSolutions ranks #596 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Emergent BioSolutions has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Days Payable compare to ELTP and NIKA?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #596 out of 919 companies for Days Payable. This places Emergent BioSolutions in the lower half of its industry. The industry median Days Payable is 90.69. Emergent BioSolutions' value of 59.81 is 34.1% below this benchmark. Historically, Emergent BioSolutions' own Days Payable has ranged from 46.37 to 104.93 over the past decade. While the company's 10-year median is 67.27 vs. the industry median of 90.69, Emergent BioSolutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current Days Payable of 59.81 is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Days Payable is 59.81, which is 11% below median its own 10-year median of 67.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.18, compared to a current price of €7.32 — trading 75.1% above its estimated fair value. The current Days Payable is 59.81, which is 11% below median its 10-year median of 67.27 and 34.1% below the Drug Manufacturers industry median of 90.69. Emergent BioSolutions' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Days Payable is 59.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €7.32 is trading 75.1% above its estimated GF Value™ of €4.18.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
Days Payable: 59.81 (11% below median its 10-year median of 67.27)
GF Value™: €4.18 vs. price of €7.32 (75.1% above fair value)
Industry Position: 34.1% below the Drug Manufacturers median (#596 of 919)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
55GF Score
Get the complete analysis for STU:ER4
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
